Candel Therapeutics to Unveil Extended Phase 3 Data for Prostate Cancer Treatment at AUA 2026
Event summary
- Candel Therapeutics will present extended follow-up data from its Phase 3 trial of aglatimagene besadenovec (CAN-2409) for localized prostate cancer at the AUA 2026 Annual Meeting on May 15, 2026.
- The presentation will feature new data showing accumulating benefits for patients treated with CAN-2409 in combination with standard radiation therapy.
- Mark G. Garzotto, M.D., will present the data in the Practice-changing, Paradigm-shifting Clinical Trials in Urology session.
- Candel's aglatimagene has received Fast Track and RMAT designations from the FDA for localized prostate cancer.
The big picture
Candel Therapeutics' upcoming presentation at the AUA 2026 Annual Meeting highlights the critical phase of its lead candidate, aglatimagene besadenovec, in the localized prostate cancer market. The extended follow-up data could solidify its position as a potential practice-changing therapy, leveraging its multimodal biological immunotherapy approach. The strategic focus on combining immunotherapies with standard treatments aligns with broader industry trends toward personalized and combination cancer therapies.
What we're watching
- Clinical Efficacy
- How the extended follow-up data will impact the perceived efficacy and market potential of aglatimagene besadenovec.
- Regulatory Pathway
- Whether the positive data will accelerate FDA approval timelines for aglatimagene in localized prostate cancer.
- Competitive Positioning
- The pace at which Candel can differentiate its immunotherapy platform in the crowded prostate cancer treatment landscape.
Related topics